PDCD1 and osteosarcoma: The tumor biospecimens of three patients were available for assessing PD-L1 and TGF-β expression (Fig. 5 A-F), which were from one osteosarcoma with rapid tumor progression after TQB2858 treatment (patient number 01010 in Table 3), one osteosarcoma with durable SD (patient number 01002 in Table 3), and one ASPS with a durable response who had previously progressed upon anti-PD-1 therapy (patient number 01007 in Table 3).